Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
March 2011
Article
volume 40, issue 1 pp 173-185.
| Related Files |
|---|
|
Redirect to publisher's version
(publisher's version.url.txt, 43 bytes) |
Repository contains one additional file which is not publicly available
Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111Indium-, 90Yttrium-, or 177Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. If kidney protective agents are used, the side-effects are few and mild, and the median duration of the therapy response is 30 and 40 months, respectively. Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice.
Keywords
- human
- priority journal
- myelodysplastic syndrome
- overall survival
- review
- treatment duration
- treatment response
- cancer survival
- quality of life
- drug efficacy
- drug dose escalation
- drug megadose
- bone marrow suppression
- side effect
- thrombocytopenia
- abdominal pain
- nausea
- single drug dose
- leukemia
- multiple cycle treatment
- tumor volume
- survival rate
- liver toxicity
- progression free survival
- retreatment
- hair loss
- vomiting
- pancreas tumor
- neuroendocrine tumor
- creatinine clearance
- yttrium 90
- Gastroenteropancreatic neuroendocrine tumor
- Peptide receptor radionuclide therapy
- 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid y 90
- Somatostatin receptor
- abdominal discomfort
- Targeted radionuclide therapy
- gastropancreatic neuroendocrine tumor
- hematologic disease
- octreotide[3 tyrosine] 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid lu 177
- octreotide[3 tyrosine] 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid y 90
- pentetate indium in 111; radioisotope; somatostatin receptor; unclassified drug
